Skip to main content

Mereo BioPharma Group plc

MREO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001719714

No open-market purchases or sales by Mereo BioPharma Group plc insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $18.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Mereo BioPharma Group plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Mereo BioPharma Group plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Mereo BioPharma Group plc
NameTitleLast reported holdingLast filingFilings, past year
Wyzga Michael SDirector25,050Feb 27, 20261
Pakianathan DeepikaDirector0Feb 27, 20261
Yoskowitz Marc JDirector–Feb 27, 20261
Jenkins AnnalisaDirector–Feb 27, 20261
Jacquet PierreDirector–Feb 27, 20261
Bender JeremyDirector12,550IndirectFeb 27, 20261
Shames DanielDirector–Feb 27, 20261
Ekblom AndersDirector–Feb 27, 20261
Scots-Knight DeniseChief Executive Officer808,921Feb 2, 20261
Lewicki John A.Chief Scientific Officer78,630Feb 2, 20261
Sermon CharlesGeneral Counsel219,061Feb 2, 20261
Fox Christine AnnChief Financial Officer89,285Feb 2, 20261
Hughes-Wilson AlexandraSee Remarks50,475Feb 2, 20261
Rubric Capital Management LP10% Owner–Jun 17, 20240
Rosen David Efraim10% Owner–Jun 17, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 16, 2024 (view filing)Sep 12-134 daysScots-Knight DeniseChief Executive OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−88.7K$4.30−$381.3K−9.9%808.9K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysLewicki John A.Chief Scientific OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−16.1K$4.30−$69.5K−17.0%78.6K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysSermon CharlesGeneral CounselSSaleAmerican Depositary Shares representing Ordinary Shares−30.9K$4.30−$133.0K−12.4%219.1K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysFox Christine AnnChief Financial OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−28.3K$4.30−$121.6K−24.1%89.3K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysHughes-Wilson AlexandraSee RemarksSSaleAmerican Depositary Shares representing Ordinary Shares−148.1K$4.30−$637.0K−74.6%50.5K after4 lots
Aug 23, 2024 (view filing)Aug 221 dayPakianathan DeepikaDirectorSSaleAmerican Depositary Shares representing Ordinary Shares−105.2K$4.43−$466.2K−100.0%0 after
Jun 27, 2024 (view filing)Jun 25-262 daysSermon CharlesGeneral CounselSSaleAmerican Depositary Shares representing Ordinary Shares−46.4K$3.48−$161.5K−20.1%184.4K after2 lots
Jun 27, 2024 (view filing)Jun 25-262 daysLewicki John A.Chief Scientific OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−24.2K$3.48−$84.3K−33.2%48.8K after2 lots
Jun 27, 2024 (view filing)Jun 25-262 daysFox Christine AnnChief Financial OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−42.4K$3.48−$147.7K−42.4%57.6K after2 lots
Jun 27, 2024 (view filing)Jun 25-262 daysScots-Knight DeniseChief Executive OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−133.0K$3.48−$463.0K−15.8%709.5K after2 lots
Jun 27, 2024 (view filing)Jun 25-262 daysHughes-Wilson AlexandraSee RemarksSSaleAmerican Depositary Shares representing Ordinary Shares−33.1K$3.48−$115.3K−48.9%34.5K after2 lots